A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.
Transcript:
Ritu Salani, MD, MBA: The next trial progress that I want to highlight is the RAINBO MMRd-GREEN trial, which is a phase 3 trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk mismatch repair deficient endometrial cancer. This is an open-label randomized phase 3 trial that's looking at durvalumab once every 4 weeks combined with radiotherapy or radiotherapy alone, for early-stage high-risk patients. Once again, [we are] moving immunotherapy even earlier in the landscape of the treatment. It is going to focus on this mismatch repair deficient endometrial cancers after hysterectomy and staging surgery. Using this molecular classification, we're targeting that high-risk group, so this study will also help inform practice. GY020 is a similar study looking at pembrolizumab in this setting. We're really looking forward to these results to see how this will continue to help inform practice.
Transcript edited for clarity.
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
April 18th 2024During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Read More
Ghamande Reviews Latest Chemoimmunotherapy Trials for Endometrial Cancer
March 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.
Read More